Vascular Malformations
Vascular Malformations
What You'll Learn
- Classify the five types of cerebral vascular malformations by flow characteristics, hemorrhage risk, and imaging appearance
- Identify clinical features that distinguish AVMs from cavernous malformations from dural AVFs
- Apply the Spetzler-Martin grading scale for AVMs and the Cognard/Borden classifications for dAVFs to guide treatment decisions
- Understand the ARUBA trial findings and their implications for unruptured AVM management
- Recognize the genetic basis of familial cavernous malformations (CCM1/CCM2/CCM3) and HHT (ENG, ACVRL1, SMAD4)
- Distinguish aggressive from benign dAVFs based on the presence of cortical venous drainage
- Explain why developmental venous anomalies (DVAs) should NEVER be treated and their association with cavernomas
- Diagnose spinal dural arteriovenous fistulas (Foix-Alajouanine syndrome) and understand why they are commonly missed
HighYield Pearls
- AVM annual rupture risk: 2–4% per year — rebleed risk highest in the first year after initial hemorrhage.
- Spetzler-Martin grade: size + eloquence + venous drainage (1–5); grades 1–2 favor microsurgery, grades 4–5 carry high surgical morbidity.
- ARUBA trial: in unruptured AVMs, medical management was superior to intervention over short/intermediate follow-up — external validity is debated, but the board takeaway is medical management for unruptured AVMs.
- Cavernoma on MRI: popcorn/mulberry T2 lesion with hemosiderin rim, strongly hypointense on T2*/SWI — angio-occult (not seen on DSA).
- Familial CCM: AD inheritance, CCM1/KRIT1, CCM2/MGC4607, CCM3/PDCD10 — multiple lesions on SWI is the giveaway.
- DVA = caput medusae: normal venous drainage variant — NEVER resect (causes venous infarction); often coexists with cavernoma.
- dAVF danger sign: cortical venous reflux (Borden II/III, Cognard IIb–V) ≥ high rupture, dementia, myelopathy → urgent embolization.
- Pulsatile tinnitus + bruit: transverse-sigmoid dAVF until proven otherwise.
- HHT (Osler-Weber-Rendu): epistaxis + mucocutaneous telangiectasias + pulmonary AVM → paradoxical emboli causing stroke or brain abscess; screen with brain MRI + bubble TTE/chest CT.
- Foix-Alajouanine / spinal dural AVF: older man with progressive lower-extremity myelopathy + T2 cord hyperintensity + flow voids — commonly missed; treat with endovascular embolization or surgical interruption depending on arterial anatomy and embolic access.
- Vein of Galen malformation: neonate with high-output heart failure + macrocrania + cranial bruit → staged endovascular embolization.
🔍 Quick ReferenceImaging · Clinical · Genetics / treatment
Imaging signatures
- Popcorn / mulberry lesion with hemosiderin rim on T2*/SWI → cavernous malformation
- Caput medusae / medusa head of dilated medullary veins draining to one transcortical vein → developmental venous anomaly (DVA)
- Brushstroke contrast enhancement in the pons with no edema or mass effect → capillary telangiectasia
- Serpentine flow voids with nidus and early draining vein on DSA → brain AVM
- Dorsal cord T2 hyperintensity + perimedullary flow voids on spinal MRI → spinal dural AVF (Foix-Alajouanine)
- Angio-occult lesion (invisible on DSA) but obvious on SWI → cavernoma
Clinical phenotype / risk
- Pulsatile tinnitus in an adult → transverse-sigmoid dural AVF
- Neonate with high-output heart failure + macrocephaly + cranial bruit → Vein of Galen malformation
- Recurrent epistaxis + lip/tongue telangiectasias + brain abscess or paradoxical stroke → HHT / Osler-Weber-Rendu with pulmonary AVM
- Progressive lower-extremity myelopathy in older man → spinal dural AVF (type I)
- Port-wine stain in V1 distribution + seizures + leptomeningeal enhancement → Sturge-Weber syndrome
- Limb hypertrophy + capillary stain + high-flow extremity AVM → Parkes-Weber syndrome
- Posterior fossa malformation + facial hemangioma + arterial anomaly → PHACE syndrome
Genetics / treatment
- KRIT1 / CCM1, MGC4607 / CCM2, PDCD10 / CCM3 (AD, multiple lesions) → familial cerebral cavernous malformation
- ENG (endoglin), ACVRL1, SMAD4 mutations → HHT / Osler-Weber-Rendu
- GNAQ somatic mosaic mutation → Sturge-Weber syndrome
- RASA1 or EPHB4 heterozygous pathogenic variant (autosomal dominant) → capillary malformation-AVM (CM-AVM) syndrome; RASA1 can include Parkes-Weber phenotype
- Gamma Knife stereotactic radiosurgery (2–3 years to obliterate; latency rebleed risk) → small / deep / eloquent AVM
- Onyx endovascular embolization → high-risk dural AVF with cortical venous reflux
- Coil embolization of pulmonary AVM → HHT (prevents paradoxical embolism / brain abscess)
- Endovascular embolization or surgical interruption of dural feeder at the radicular vein → type I spinal dural AVF (choice depends on arterial anatomy and embolic access; surgery definitive when embolization unsuitable/incomplete)
Overview & Classification
General Principles
- Cerebral vascular malformations are a heterogeneous group of abnormal vascular structures involving arteries, capillaries, or veins
- Classification is based on the McCormick histological system — classic histologic types: AVM, cavernous malformation, capillary telangiectasia, and DVA / venous angioma (dAVFs are acquired arteriovenous shunts and are not part of the McCormick histologic types)
- Key distinguishing features: flow type (high vs. low), presence of intervening brain parenchyma, hemorrhage risk, and angiographic visibility
- Capillary telangiectasias represent a fifth, typically incidental, category
Comprehensive Comparison of Vascular Malformations
| Feature | AVM | Cavernous Malformation | Dural AVF | DVA |
|---|---|---|---|---|
| Flow type | High-flow | Low-flow | High-flow | Low-flow |
| Pathology | Nidus: direct arteriovenous shunting; no capillary bed | Sinusoidal channels without intervening brain parenchyma | Fistula between dural arteries and dural sinuses/cortical veins | Radial medullary veins draining into a single collecting vein |
| Congenital vs. acquired | Congenital | Congenital (sporadic or familial) | Acquired | Congenital (developmental variant) |
| Prevalence | 0.1% | 0.4–0.8% | 10–15% of intracranial vascular malformations | Most common (60% of all) |
| Hemorrhage risk | 2–4% per year | 0.5–3% per year | Variable — depends on cortical venous drainage | Extremely rare |
| Angiography | Visible (nidus, feeders, draining veins) | Angiographically occult | Visible (early venous filling, fistula site) | Visible (caput medusae in venous phase) |
| MRI appearance | Flow voids, T2 signal abnormality | “Popcorn” lesion with hemosiderin ring | Dilated vessels, flow voids, edema | Caput medusae, enhancing collector vein |
| Treatment | Microsurgery, radiosurgery, embolization, observation | Microsurgery for symptomatic; observation | Endovascular embolization, microsurgery, radiosurgery | Do NOT treat |
💎 Board Pearl
- DVA = most common vascular malformation overall. AVM = most clinically significant. Cavernoma = second most common symptomatic lesion. Key board question: “Angiographically occult” lesion with seizures → think cavernous malformation
Arteriovenous Malformations (AVMs)
Pathology & Pathophysiology
Structure
- Nidus: tangled network of dysplastic vessels forming direct arteriovenous shunts — no intervening capillary bed
- Feeding arteries: enlarged, high-flow arteries supplying the nidus; may develop flow-related aneurysms (7–20% of cases)
- Draining veins: arterialized veins carrying high-pressure oxygenated blood; prone to rupture
- Brain parenchyma is interspersed within the nidus (distinguishes from cavernoma)
- Gliosis and hemosiderin deposits surround the nidus
Hemodynamics
- Arteriovenous shunting: low-resistance pathway → high flow through nidus
- Steal phenomenon: blood diverted from adjacent normal brain tissue → chronic hypoperfusion → progressive neurological deficits
- Venous hypertension: arterialized pressure transmitted to venous system → hemorrhage risk, edema
- Associated aneurysms: intranidal (within nidus), flow-related (on feeding arteries), or remote — all increase hemorrhage risk
Epidemiology
- Prevalence: ~0.1% (1 in 1,000); incidence ~1 per 100,000 per year
- Typically present in young adults (20–40 years); most diagnoses before age 50
- No sex predominance; slight male predilection for hemorrhage
- Account for 1–2% of all strokes but up to 33% of hemorrhagic strokes in young adults
- 90% are supratentorial; 10% are infratentorial (higher hemorrhage risk)
Clinical Presentation
Hemorrhage (Most Common — 50–65%)
- Annual hemorrhage risk: 2–4% per year for unruptured; ~4.5% per year in first year after initial hemorrhage
- Lifetime risk approximation (simplified): 105 − patient age (in years) = approximate lifetime risk in %
- Typically intraparenchymal; may extend to subarachnoid or intraventricular space
- AVM hemorrhage generally has lower mortality than hypertensive ICH (~10% vs. ~40%)
Seizures (20–25%)
- More common with cortical AVMs, especially frontal and temporal locations
- Mechanism: gliosis, hemosiderin deposition, ischemia from steal phenomenon
- May be the presenting symptom, especially with large superficial AVMs
Headache (15%)
- Migraine-like headaches, sometimes with aura
- May mimic cluster headaches if in posterior fossa
Progressive Neurological Deficits (5–10%)
- Vascular steal: chronic hypoperfusion of adjacent brain tissue
- Progressive hemiparesis, cognitive decline, or visual field deficits
- More common with large, high-flow AVMs
Hemorrhage Risk Factors
- Prior hemorrhage (strongest risk factor; recurrent hemorrhage rate ~4.5%/year in first year)
- Deep location (basal ganglia, thalamus, brainstem)
- Deep venous drainage (single deep draining vein)
- Associated aneurysms (intranidal or feeding artery)
- Small nidus size (paradoxically higher pressure per vessel)
- Infratentorial location
- Venous outflow stenosis or restriction
🧪 Risk Stratification Mnemonic
- “Small, Deep, and Drained Deep” = highest hemorrhage risk
- Small AVMs have higher intranidal pressure (less compliance) → counterintuitively higher rupture risk per year
- However, large AVMs accumulate greater lifetime risk of hemorrhage and are more difficult to treat
Spetzler-Martin Grading Scale
Grading Components
| Feature | Points |
|---|---|
| Size of nidus | |
| < 3 cm | 1 |
| 3–6 cm | 2 |
| > 6 cm | 3 |
| Eloquent cortex | |
| Non-eloquent | 0 |
| Eloquent (sensorimotor, language, visual, thalamus, hypothalamus, internal capsule, brainstem, cerebellar peduncles, deep cerebellar nuclei) | 1 |
| Venous drainage | |
| Superficial only | 0 |
| Any deep venous drainage | 1 |
Interpretation
| Grade | Score | Surgical Risk | Management Approach |
|---|---|---|---|
| I | 1 | Low (~0% morbidity) | Microsurgical resection preferred |
| II | 2 | Low (~5%) | Microsurgical resection preferred |
| III | 3 | Moderate (~12–18%) | Multimodal (embolization + surgery or radiosurgery) |
| IV | 4 | High (~20–30%) | Often observation; multimodal if ruptured |
| V | 5 | Very high (~30–50%) | Typically observation (inoperable) |
💎 Board Pearl
- Spetzler-Martin grade = Size + Eloquence + Deep drainage. Maximum score = 5. Grades I–III are generally considered surgical candidates. Grades IV–V are typically managed conservatively unless ruptured. A “Grade VI” is sometimes used informally for inoperable AVMs
ARUBA Trial
Study Design & Key Findings
- A Randomized trial of Unruptured Brain AVMs (ARUBA) — published 2014, New England Journal of Medicine
- Population: 226 patients with unruptured AVMs randomized to medical management alone vs. interventional therapy (surgery, embolization, radiosurgery, or combination)
- Primary outcome: Stroke or death
- Result: Medical management was superior to intervention — event rate 10.1% (medical) vs. 30.7% (intervention) at mean follow-up of 33 months
- Risk ratio: 0.27 (95% CI 0.14–0.54) favoring medical management
- Trial stopped early due to superiority of medical management
Criticisms & Limitations
- Short follow-up (33 months) — AVMs are lifelong conditions; benefits of treatment may emerge over decades
- Heterogeneous treatment arm: mixed surgical, endovascular, and radiosurgery approaches; not all centers were high-volume
- Selection bias: excluded high-grade (IV–V) AVMs, but also included many low-grade AVMs that might not have been treated in practice
- No stratification by Spetzler-Martin grade within the intervention arm
- Radiosurgery effects take 2–3 years for full obliteration — short follow-up may underestimate benefit
- Many AVM specialists continue to recommend treatment for low-grade (I–II) AVMs in young patients
🧪 ARUBA in Clinical Context
- Board answer: ARUBA showed medical management > intervention for unruptured AVMs in short-term follow-up
- Clinical reality: many neurovascular centers still treat low-grade AVMs in young patients; results remain controversial
- ARUBA does NOT apply to ruptured AVMs — intervention is generally recommended after hemorrhage
- Long-term follow-up data (ARUBA-LT) continues to favor medical management at 12 years, but debate persists
Treatment Options
Microsurgical Resection
- Gold standard for Spetzler-Martin grades I–III
- Provides immediate and complete cure if total resection is achieved
- Cure rate: >95% for grades I–II
- Risk of normal perfusion pressure breakthrough (NPPB): after removal of high-flow AVM, surrounding brain may develop edema/hemorrhage from loss of autoregulation
- Staged embolization before surgery reduces nidus size and intraoperative blood loss
Stereotactic Radiosurgery (Gamma Knife / CyberKnife)
- Best for small (<3 cm) and deep AVMs not amenable to surgery
- Obliteration rate: ~80% at 3 years for lesions <3 cm
- Delayed effect: 2–3 years for complete obliteration via radiation-induced vessel wall thickening and thrombosis
- Patient remains at hemorrhage risk during the latency period
- Adverse effects: radiation necrosis, edema, cyst formation
Endovascular Embolization
- Primarily used as adjunctive therapy before surgery or radiosurgery to reduce nidus size
- Rarely curative as monotherapy (<20% complete obliteration); highest success with small AVMs with few feeders
- Embolic agents: n-butyl cyanoacrylate (nBCA/Onyx), coils, particles
- Risks: stroke, hemorrhage (from premature venous occlusion), cranial nerve injury
- Targeted embolization of associated aneurysms reduces hemorrhage risk
Multimodal Approach
- Combines embolization + surgery, or embolization + radiosurgery
- Particularly useful for grade III AVMs
- Embolization reduces nidus volume → improves surgical safety or radiosurgery effectiveness
Hereditary Hemorrhagic Telangiectasia (HHT) / Osler-Weber-Rendu Syndrome
Genetics & Pathophysiology
- Autosomal dominant disorder of vascular dysplasia
- HHT1: ENG gene (endoglin) on chromosome 9 → higher risk of pulmonary and cerebral AVMs
- HHT2: ACVRL1 gene (ALK1) on chromosome 12 → higher risk of hepatic AVMs
- Juvenile polyposis-HHT overlap: SMAD4 gene
- Prevalence: ~1 in 5,000–8,000
Clinical Features (Curaçao Criteria — need ≥3 for definite diagnosis)
- Epistaxis: spontaneous, recurrent nosebleeds (most common feature, >90%)
- Telangiectasias: lips, oral mucosa, fingers, nose
- Visceral AVMs: pulmonary (30–50% in HHT1), hepatic (30–70% in HHT2), cerebral (10–20%), GI, spinal
- Family history: first-degree relative with HHT
Neurological Complications
- Cerebral AVMs: present in 10–20% of HHT patients (especially HHT1); often multiple, small
- Brain abscess: from paradoxical embolism through pulmonary AVMs (bypassing pulmonary capillary filter)
- Ischemic stroke: paradoxical embolism through pulmonary AVMs
- Spinal AVMs: less common but may cause myelopathy
- Screening: all HHT patients should undergo brain MRI and contrast echocardiography (bubble study) for pulmonary AVMs
💎 Board Pearl
- HHT + brain abscess = think paradoxical embolism through pulmonary AVM. Pulmonary AVMs bypass the pulmonary capillary filter, allowing septic emboli to reach the brain. All HHT patients need pulmonary AVM screening. HHT1 (ENG) has highest cerebral AVM risk; HHT2 (ACVRL1) has highest hepatic AVM risk
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.